Harmony Biosciences Holdings (HRMY) Asset Writedowns and Impairment (2022 - 2026)
Harmony Biosciences Holdings (HRMY) reported Asset Writedowns and Impairment of $560000.0 for Q1 2026, up 19.91% on a YoY basis from $467000.0 in Q1 2025, and up 39.3% sequentially from $402000.0 in Q4 2025.
Harmony Biosciences Holdings (HRMY) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 5 years of Asset Writedowns and Impairment data on file, last reported at $560000.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment rose 19.91% year-over-year to $560000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 32.48% YoY), and the FY2025 full-year result was $1.3 million, down 36.9% from the prior year.
- Asset Writedowns and Impairment rose to $560000.0 in Q1 2026, from $402000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $659000.0 in Q2 2024 to a low of -$9000.0 in Q3 2025.
- A 5-year average of $428176.5 and a median of $465000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment jumped 68.75% in 2023 and plunged 101.83% in 2025, its largest moves.
- Tracing HRMY's Asset Writedowns and Impairment over 5 years: stood at $484000.0 in 2022, then increased by 5.37% to $510000.0 in 2023, then fell by 5.69% to $481000.0 in 2024, then retreated by 16.42% to $402000.0 in 2025, then surged by 39.3% to $560000.0 in 2026.
- Business Quant data shows HRMY's Asset Writedowns and Impairment at $560000.0 in Q1 2026, $402000.0 in Q4 2025, and -$9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Harmony Biosciences Holdings | 2.09 Bn | 1.57 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 560,000.00 |
| Mar 31, 2026 | 560,000.00 |
| Dec 31, 2025 | 402,000.00 |
| Dec 31, 2025 | 402,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Mar 31, 2025 | 467,000.00 |
| Dec 31, 2024 | 481,000.00 |
| Dec 31, 2024 | 481,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 467,000.00 |
| Mar 31, 2024 | 467,000.00 |
| Dec 31, 2023 | 510,000.00 |
| Dec 31, 2023 | 510,000.00 |